Detalhe da pesquisa
1.
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med
; 386(23): 2188-2200, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443106
2.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Clin Infect Dis
; 76(7): 1247-1256, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411267
3.
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Lancet
; 395(10234): 1423-1433, 2020 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32197105
4.
GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.
Nat Commun
; 14(1): 3274, 2023 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280238
5.
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Respir Med
; 10(10): 985-996, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688164
6.
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Lancet Infect Dis
; 17(6): 615-625, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28365225
7.
Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America.
Am J Trop Med Hyg
; 93(1): 18-23, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26013373
8.
Challenges in the clinical development of a dengue vaccine.
Curr Opin Virol
; 3(3): 352-6, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23747120
9.
Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
Am J Trop Med Hyg
; 89(6): 1058-1065, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24189367
10.
Efficacy of a tetravalent dengue vaccine in healthy children aged 416 years: a randomised, placebo-controlled, phase 3 trial
Artigo
em Inglês
| ARCA | ID: arc-41467